{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:57:29Z","timestamp":1761101849848},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.pcl.2008.01.010","type":"journal-article","created":{"date-parts":[[2008,3,31]],"date-time":"2008-03-31T20:43:43Z","timestamp":1206996223000},"page":"357-376","source":"Crossref","is-referenced-by-count":13,"title":["Advances in Hemophilia: Experimental Aspects and Therapy"],"prefix":"10.1016","volume":"55","author":[{"given":"Nidra I.","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Keith","family":"Hoots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcl.2008.01.010_bib1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/asheducation-2005.1.429","article-title":"New perspectives in hemophilia treatment","author":"Kessler","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Suppl 1","key":"10.1016\/j.pcl.2008.01.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.9.s1.17.x","article-title":"Consensus perspectives on prophylactic therapy for haemophilia: summary statement","volume":"9","author":"Berntorp","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.pcl.2008.01.010_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jacc.2004.02.038","article-title":"Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"43","author":"Gali\u00e8","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcl.2008.01.010_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcl.2008.01.010_bib5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized","volume":"105","author":"Astermark","year":"1999","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.pcl.2008.01.010_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002770050436","article-title":"Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis","volume":"77","author":"Funk","year":"1998","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.pcl.2008.01.010_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2516.1998.440413.x","article-title":"When should prophylactic treatment in patients with haemophilia A and B start?\u2013The German experience","volume":"4","author":"Kreuz","year":"1998","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.pcl.2008.01.010_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00043426-199123000-00006","article-title":"Prophylaxis with factor concentrates in preventing hemophilic arthropathy","volume":"13","author":"Petrini","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1016\/j.pcl.2008.01.010_bib9","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V99.7.2337","article-title":"The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia","volume":"99","author":"Fischer","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcl.2008.01.010_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group","volume":"236","author":"Aledort","year":"1994","journal-title":"J\u00a0Intern Med"},{"issue":"3","key":"10.1016\/j.pcl.2008.01.010_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0022-3476(96)70076-8","article-title":"Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis","volume":"129","author":"Smith","year":"1996","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.pcl.2008.01.010_bib12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1046\/j.1365-2516.1998.440498.x","article-title":"Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group","volume":"4","author":"Szucs","year":"1998","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.pcl.2008.01.010_bib13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1046\/j.1365-2516.2002.00695.x","article-title":"Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome","volume":"8","author":"Fischer","year":"2002","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.pcl.2008.01.010_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2516.2001.00471.x","article-title":"What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?","volume":"7","author":"Petrini","year":"2001","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.pcl.2008.01.010_bib15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1365-2141.2001.02580.x","article-title":"Long-term outcome of individualized prophylactic treatment of children with severe haemophilia","volume":"112","author":"van den Berg","year":"2001","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.pcl.2008.01.010_bib16","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pcl.2008.01.010_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2516.2002.00645.x","article-title":"The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents","volume":"8","author":"Villar","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.pcl.2008.01.010_bib18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1055\/s-0038-1656088","article-title":"Desmopressin (DDAVP) enhances platelet adhesion to the extracellular matrix of cultured human endothelial cells through increased expression of tissue factor","volume":"77","author":"Galves","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcl.2008.01.010_bib19","first-page":"1","article-title":"Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients","volume":"2","author":"Winterbottom","year":"2002","journal-title":"Journal of Applied Research"},{"issue":"6650","key":"10.1016\/j.pcl.2008.01.010_bib20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/39057","article-title":"Transmissions to mice indicate that \u2018new variant\u2019 CJD is caused by the BSE agent","volume":"389","author":"Bruce","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pcl.2008.01.010_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jamcollsurg.2007.03.020","article-title":"A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis","volume":"205","author":"Chapman","year":"2007","journal-title":"J Am Coll Surg"},{"issue":"3","key":"10.1016\/j.pcl.2008.01.010_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1046\/j.0007-1048.2001.03324.x","article-title":"Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors","volume":"116","author":"O'Connell","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.pcl.2008.01.010_bib23","first-page":"531","article-title":"Treatment of patients with factor VIII and IX inhibitors with special focus on the use of recombinant factor VIIa","volume":"82","author":"Hedner","year":"1999","journal-title":"Thromb Haemost"},{"issue":"328","key":"10.1016\/j.pcl.2008.01.010_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00003086-199607000-00003","article-title":"Effects of hemophilia on articulations of children and adults","author":"Rodriguez-Merchan","year":"1996","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.pcl.2008.01.010_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0037-1613015","article-title":"Radionuclide synovectomy for hemophilic arthropathy: a comprehensive review of safety and efficacy and recommendation for a standarized treatment protocol","volume":"87","author":"Dunn","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcl.2008.01.010_bib26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00043426-200210000-00007","article-title":"32P radiosynoviorthesis in children with hemophilia","volume":"24","author":"Manco-Johnson","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.pcl.2008.01.010_bib27","article-title":"Is there an increased risk of cancer associated with radiosynoviorthesis?","volume":"12","author":"Infante-Rivard","year":"2006","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.pcl.2008.01.010_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2516.2006.01360.x","article-title":"Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors","volume":"12","author":"Astermark","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.pcl.2008.01.010_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2516.1999.00300.x","article-title":"Incidence of inhibitors in haemophilia A patients\u2014a review of recent studies of recombinant and plasma-derived factor VIII concentrates","volume":"5","author":"Scharrer","year":"1999","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.pcl.2008.01.010_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2005-04-1371","article-title":"Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A","volume":"107","author":"Goudemand","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pcl.2008.01.010_bib31","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2006-11-056317","article-title":"Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2008.01.010_bib32","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1073\/pnas.85.16.6152","article-title":"Epitope mapping of human FVIII inhibitor antibodies by deletion analysis of FVIII fragments expressed in Escherichia coli","volume":"85","author":"Scandella","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.pcl.2008.01.010_bib33","first-page":"16","article-title":"The role of plasma-derived factor VIII\/von Willebrand factor concentrates in the treatment of hemophilia A patients","volume":"88","author":"Auerswald","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.pcl.2008.01.010_bib34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1055\/s-0038-1650655","article-title":"Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor","volume":"76","author":"Suzuki","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcl.2008.01.010_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1365-2516.2001.00526.x","article-title":"Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII","volume":"7","author":"Gensana","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.pcl.2008.01.010_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0037-1613191","article-title":"von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model","volume":"88","author":"Behrmann","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcl.2008.01.010_bib37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2516.2006.01201.x","article-title":"Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate","volume":"12","author":"Gringeri","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.pcl.2008.01.010_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2516.2007.01484.x","article-title":"Immune tolerance induction with a high purity von Willebrand factor\/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response","volume":"13","author":"Gringeri","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.pcl.2008.01.010_bib39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0022-2143(99)90164-6","article-title":"Clinical applications of anti CD 20 antibodies","volume":"134","author":"Gopal","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pcl.2008.01.010_bib40","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD 20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2008.01.010_bib41","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","article-title":"Rituximab for the treatment of refractory autoimmune hemolytic anemia in children","volume":"101","author":"Zecca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2008.01.010_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2516.2005.01170.x","article-title":"Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience","volume":"12","author":"Carcao","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.pcl.2008.01.010_bib43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2516.2006.01215.x","article-title":"Rituximab for adolescents with haemophilia and high titre inhibitors","volume":"12","author":"Fox","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.pcl.2008.01.010_bib44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0092-8674(85)90094-7","article-title":"The molecular genetics of hemophilia: blood clotting factors VIII and IX","volume":"42","author":"Lawn","year":"1985","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pcl.2008.01.010_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2003-37936","article-title":"The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development","volume":"29","author":"Goodeve","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.pcl.2008.01.010_bib46","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1538-7836.2007.02410.x","article-title":"Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment","volume":"5","author":"Pierce","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pcl.2008.01.010_bib47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.moh.0000239700.94555.b1","article-title":"Gene therapy for hemophilia","volume":"13","author":"Ponder","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.pcl.2008.01.010_bib48","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2008.01.010_bib49","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1111\/j.1538-7836.2005.01367.x","article-title":"The promise and challenges of bioengineered recombinant clotting factors","volume":"3","author":"Pipe","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.pcl.2008.01.010_bib50","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pcl.2008.01.010_bib51","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1592\/phco.23.9.3S.32886","article-title":"Pegylation: engineering improved biopharmaceuticals for oncology","volume":"23","author":"Molineaux","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pcl.2008.01.010_bib52","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1160\/TH04-08-0485","article-title":"Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy","volume":"93","author":"Baru","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pcl.2008.01.010_bib53","first-page":"1","article-title":"Liposomal drug delivery systems\u2014clinical applications","volume":"55","author":"Goyal","year":"2005","journal-title":"Acta Pharm"},{"key":"10.1016\/j.pcl.2008.01.010_bib54","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2006-03-008276","article-title":"Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII (Kogenate (R) FS) reconstituted with pegylated liposomes","volume":"108","author":"Spira","year":"2006","journal-title":"Blood"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395508000655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395508000655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T22:11:54Z","timestamp":1630966314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395508000655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0031395508000655"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2008.01.010","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}